19989-35-6 Usage
Description
Ethanone, 1-(6-benzothiazolyl)(9CI) is a chemical compound characterized by the molecular formula C10H7NOS. It is a ketone derivative featuring a benzothiazolyl group attached to the carbon atom, which endows it with unique chemical and physical properties. Ethanone, 1-(6-benzothiazolyl)(9CI) holds potential in various domains, such as organic synthesis and medicinal chemistry, due to its structural attributes and functional group versatility.
Uses
Used in Organic Synthesis:
Ethanone, 1-(6-benzothiazolyl)(9CI) serves as a valuable building block in the synthesis of a range of pharmaceuticals, agrochemicals, and other biologically active compounds. Its ketone and benzothiazolyl functionalities provide a foundation for further chemical modifications and the creation of novel molecules with desired properties.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, Ethanone, 1-(6-benzothiazolyl)(9CI) is utilized as a key intermediate for the development of new drugs. Its structural features can be exploited to design molecules with specific biological activities, potentially leading to the discovery of new therapeutic agents.
Used in Fluorescent Probes and Sensors:
Ethanone, 1-(6-benzothiazolyl)(9CI) exhibits fluorescent properties, making it a candidate for the development of fluorescent probes and sensors. These can be applied in biological imaging and detection, allowing for the observation and measurement of various biological processes and interactions at the molecular level.
Used in Research and Development:
In research and development settings, Ethanone, 1-(6-benzothiazolyl)(9CI) can be employed to explore its chemical reactivity, investigate its interactions with other molecules, and study its potential applications in various industries. This may lead to the discovery of new uses and applications for this compound.
Check Digit Verification of cas no
The CAS Registry Mumber 19989-35-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,9,9,8 and 9 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 19989-35:
(7*1)+(6*9)+(5*9)+(4*8)+(3*9)+(2*3)+(1*5)=176
176 % 10 = 6
So 19989-35-6 is a valid CAS Registry Number.
InChI:InChI=1/C9H7NOS/c1-6(11)7-2-3-8-9(4-7)12-5-10-8/h2-5H,1H3
19989-35-6Relevant articles and documents
Generation and Trapping of 4-Methylene-5-(bromomethylene)-4,5-dihydrothiazole with Dienophiles
Hariri, Mouaffak Al,Jouve, Karine,Pautet, Félix,Domard, Monique,Fenet, Bernard,Fillion, Houda
, p. 405 - 410 (1997)
4-(Bromomethyl)-5-(dibromomethyl)thiazole (1) was prepared in good yields by bromination of 4,5-dimethylthiazole with 3.3 equiv of NBS in the presence of AIBN. Treatment of 1 with sodium iodide led to a thiazole o-quinodimethane 2 which was trapped in sit
CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME
-
Page/Page column 298, (2018/09/21)
The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful as modulators of Hepatitis B (HBV) core protein, and methods of treating Hepatitis B (HBV) infection.
Development of new highly potent imidazo[1,2-b[pyridazines targeting Toxoplasma gondii calcium-dependent protein kinase 1
Moine, Espérance,Dimier-Poisson, Isabelle,Enguehard-Gueiffier, Cécile,Logé, Cédric,Pénichon, Mélanie,Moiré, Nathalie,Delehouzé, Claire,Foll-Josselin, Beátrice,Ruchaud, Sandrine,Bach, Stéphane,Gueiffier, Alain,Debierre-Grockiego, Fran?oise,Denevault-Sabourin, Caroline
, p. 80 - 105 (2015/11/02)
Using a structure-based design approach, we have developed a new series of imidazo[1,2-b]pyridazines, targeting the calcium-dependent protein kinase-1 (CDPK1) from Toxoplasma gondii. Twenty derivatives were thus synthesized. Structure-activity relationships and docking studies confirmed the binding mode of these inhibitors within the ATP binding pocket of TgCDPK1. Two lead compounds (16a and 16f) were then identified, which were able to block TgCDPK1 enzymatic activity at low nanomolar concentrations, with a good selectivity profile against a panel of mammalian kinases. The potential of these inhibitors was confirmed in vitro on T. gondii growth, with EC50 values of 100 nM and 70 nM, respectively. These best candidates also displayed low toxicity to mammalian cells and were selected for further in vivo investigations on murine model of acute toxoplasmosis.